









Markets
/
Stocks
/
nasdaq-imnm
/

Immunome Inc

IMNM

24.880USD

+0.880+3.67%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.28BMarket Cap

LossP/E TTM



Immunome Inc

24.880

+0.880+3.67%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immunome Inc

Currency: USD Updated: 2026-02-06

Key Insights

Immunome Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.45.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immunome Inc's Score

Industry at a Glance

Industry Ranking

48 / 392

Overall Ranking

155 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Immunome Inc Highlights

StrengthsRisks

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.04M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 9.04M.

Undervalued

The company’s latest PE is -8.41, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 93.24M shares, increasing 6.55% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 202.30K shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

34.455

Target Price

+43.56%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Immunome Inc is 7.26, ranking 132 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 21.99%.

Score

Industry at a Glance

Previous score

7.37

Change

-0.11



Financials

9.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.13

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.70

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.61

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.32

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Immunome Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Immunome Inc is 5.79, ranking 363 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.41, which is -87.47% below the recent high of -1.05 and -8.40% above the recent low of -9.11.

Score

Industry at a Glance

Previous score

5.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 48/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Immunome Inc is 8.62, ranking 91 out of 392 in the Biotechnology & Medical Research industry. The average price target is 23.50, with a high of 38.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.62

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

34.455

Target Price

+30.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Immunome Inc

IMNM

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Immunome Inc is 9.22, ranking 28 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 28.49 and the support level at 20.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.05

Change

0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.216

Neutral

RSI(14)

55.525

Neutral

STOCH(KDJ)(9,3,3)

36.445

Sell

ATR(14)

1.680

Low Volatility

CCI(14)

-25.447

Neutral

Williams %R

44.249

Buy

TRIX(12,20)

0.923

Sell

StochRSI(14)

20.804

Neutral

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

25.680

Sell

MA10

25.397

Sell

MA20

24.110

Buy

MA50

21.806

Buy

MA100

18.198

Buy

MA200

13.745

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Immunome Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 84.51%, representing a quarter-over-quarter decrease of 8.80%. The largest institutional shareholder is The Vanguard, holding a total of 6.02M shares, representing 5.45% of shares outstanding, with 10.64% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

13.06M

+111.70%

T. Rowe Price Investment Management, Inc.

10.64M

+26.45%

The Vanguard Group, Inc.

Star Investors

4.88M

+8.18%

BlackRock Institutional Trust Company, N.A.

5.24M

+1.28%

Redmile Group, LLC

5.02M

+3.10%

Point72 Asset Management, L.P.

Star Investors

4.82M

+2.96%

Enavate Sciences GP, LLC

4.77M

EcoR1 Capital, LLC

4.08M

T. Rowe Price Associates, Inc.

Star Investors

3.65M

+26.05%

Opaleye Management Inc.

3.19M

-9.76%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Immunome Inc is 4.20, ranking 101 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.